Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Shenzhen Hepalink Pharma (002399 CH)
Watchlist
85
Analysis
Health Care
•
China
Shenzhen Hepalink Pharmaceutical Co., Ltd researches, produces and sells heparin pharmaceuticals products. The Company's products include heparin sodium active pharmaceutical ingredient.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
09 Jul 2015 06:01
Who's Optimistic About Pharmacy's Future in China? China Nepstar's Controlling Shareholder
China Nepstar's Chairman and his China Neptunus Drugstore Holding Ltd. (54% owner) has offered $2.60/ADS to take the company private (announcement...
Kemp Dolliver, CFA
577 Views
Share
bearish
•
Thematic (Sector/Industry)
•
01 Jul 2015 22:01
China ADR Privatizations: The Challenges of Getting the Best Deal
The stellar performance of China’s stock markets over the past twelve months (Shanghai +121%, Shenzhen +161%, and Hong Kong +17%) has led to a...
Kemp Dolliver, CFA
603 Views
Share
bullish
•
Thematic (Sector/Industry)
•
21 Feb 2015 00:02
Opening of E-commerce Channel to Change China's Drug Market
Numerous press outlets report that China’s Food & Drug Administration (CFDA) will release regulations permitting online sales of...
Kemp Dolliver, CFA
602 Views
Share
bullish
•
Thematic (Sector/Industry)
•
05 Feb 2015 16:01
Introducing Long Term Leaders - Focussed Insights for your Core Holdings
We are pleased to announce the roll out of our latest content vertical: Long Term Leaders. Under this category,  we have identified companies that...
Sumeet Singh
Follow
497 Views
Share
bullish
•
Quantitative Analysis
•
08 Mar 2026 10:15
A-H Premium Weekly (Mar 6th): Sinopec, COSCO Shipping Energy, China Coal Energy, CNOOC
We analyzed A-H premium changes in the past week and highlight A-H premium changes for Sinopec, COSCO Shipping Energy, China Coal Energy, CNOOC,...
Ke Yan, CFA, FRM
Follow
290 Views
Share
First
Previous
2
3
4
5
6
7
8
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x